| Revenue | $15.00B | ▲ +12.4% — 3rd straight Q1 of growth |
| Net Income | $685M | ▼ -46.3% |
| EPS | $0.39 | ▼ -45.8% |
| Profitability & Cash Flow | ||
| Pro Op Cash Flow · Net Margin · Gross Margin · Op Margin | ||
| Capital Returns | ||
| Pro Buybacks · Dividends · Stock-based comp · Share change | ||
| Balance Sheet | ||
| Pro Cash & equivalents · Long-term debt | ||
Abbvie Inc. (ABBV) filed its latest earnings report on July 6, 2026; detailed figures from it will appear here once available. The most recent complete reporting period is Q1 2026. Revenue was $15.00B, up 12.4% year-over-year — its 3rd straight Q1 of growth. Net income was $685M (down 46.3%) and EPS was $0.39 (down 45.8%). ABBV's next report is expected around October 5, 2026 (estimated from its filing history). Source: SEC filing.
Get ABBV earnings in your inbox
Free email alerts when this company reports. No credit card.
When does ABBV report earnings next?
Abbvie Inc. is expected to report around October 5, 2026, estimated from its filing history (the exact date is announced by the company). The Earnings Watcher sends a free email alert the day it files.
What were ABBV's latest earnings results?
Abbvie Inc. (ABBV) filed its latest earnings report on July 6, 2026; detailed figures from it will appear here once available. The most recent complete reporting period is Q1 2026. Revenue was $15.00B, up 12.4% year-over-year — its 3rd straight Q1 of growth. Net income was $685M (down 46.3%) and EPS was $0.39 (down 45.8%).
Where can I read ABBV's full earnings report?
The full earnings release, as filed with the SEC on July 6, 2026, is available on this page below the summary.
Earnings Report
Filed July 6, 2026
AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
| (in millions, except per share data) | Quarter Ended June 30, 2026 | Full-Year Ended December 31, 2026 | |||||||||||||||||||||||||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q2 2026 acquired IPR&D and milestones expense | $ | — | $ | 3.74 | $ | 3.78 | $ | 744 | $ | 14.08 | $ | 14.28 | |||||||||||||||||||||||
| Q2 2026 acquired IPR&D and milestones expense | 291 | (0.17) | (0.17) | 291 | (0.17) | (0.17) | |||||||||||||||||||||||||||||
Guidance including Q2 2026 acquired IPR&D and milestones expensea | $ | 291 | $ | 3.57 | $ | 3.61 | $ | 1,035 | $ | 13.91 | $ | 14.11 | |||||||||||||||||||||||
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted.
1